Abbott ABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...

Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch ...

MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...

The Abbott FreeStyle Libre 2 can be used as a real-time continuous glucose monitor (CGM) with an upgrade to the FreeStyle LibreLink app. Please note, the below information comes with a critical update ...

Abbott ($ABT) now has a mobile app to collect and share data for its continuous glucose monitor that doesn't require routine finger-stick calibration, FreeStyle Libre ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...

(RTTNews) - Abbott said that the U.S. Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a comprehensive digital offering for its ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

AbbottABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...